Effects of Etanercept on Sodium Taurocholate-induced Acute Pancreatitis in Rats
Overview
Authors
Affiliations
In this study, we examined the effects of etanercept (ETA) on experimentally induced pancreatitis. Acute pancreatitis was induced with Na taurocholate. ETA was simultaneously administered to treatment groups. Serum amylase and lipase activity, pancreatic histopathology, apoptosis, malondialdehyde (MDA), and myeloperoxidase enzyme activity (MPO) were assessed. Although rats in the groups 1, 2, and 3 were sacrificed 24h later, groups 4, 5, and 6 were sacrificed 5 days later. ETA treatment significantly decreased serum amylase activity (nontreated, 2636.16+/-191.94; treated, 1898.71+/-262.53; control, 506.28+/-17.31 U/L, P<0.001), lipase activity (nontreated, 3049.67+/-972.65; treated, 2538.85+/-660.45; control, 88.57+/-7.54 U/L, P<0.001), histopathologic score (nontreated, 5.43+/-0.43; treated, 2.57+/-0.20; control, 0.71+/-0.18, P<0.001), MDA (nontreated, 105.77+/-13.29; treated, 92.89+/-10.39; control, 41.26+/-2.54 nmol/g, P<0.001), and MPO (nontreated, 0.64+/-1.15; treated, 0.59+/-0.13; control, 0.17+/-0.02 units/g/wet weight, P<0.001) activity in 24-h groups. In 5-day groups, ETA treatment decreased amylase activity (nontreated, 738.67+/-48.60; treated, 497.14+/-47.25; control, 389.00+/-9.17 U/L, P<0.001), lipase activity (nontreated, 101.33+/-39.32; treated, 34.57+/-7.29; control, 23.42+/-2.12 U/L, P<0.001), histopathologic score (nontreated, 5.43+/-0.43; treated, 3.71+/-0.68; control, 0.00+/-0.00, P<0.001), MDA (nontreated, 67.91+/-4.28; treated, 60.91+/-3.57; control, 14.85+/-1.16 nmol/g, P<0.001), and MPO (nontreated, 0.36+/-0.04; treated, 0.27+/-0.02; control, 0.14+/-0.02 units/g/wet weight, P<0.001) activity. Caspase-positive cells numbers around the necrosis significantly decreased by ETA treatment in both 24-h groups (nontreated, 74.28+/-3.26; treated, 67.00+/-1.15; control, 3.85+/-0.63, P<0.001) and 5-day groups (nontreated, 79.85+/-3.01; treated, 47.85+/-5.76; control, 2.22+/-0.63, P<0.001). These results showed that ETA has an ameliorating effect on sodium taurocholate-induced acute necrotic pancreatitis.
Increasing Trends in the Pancreatitis Risk With Tumor Necrosis Factor Inhibitor Use.
Gu J, Samarneh M Cureus. 2024; 16(11):e74245.
PMID: 39712842 PMC: 11663436. DOI: 10.7759/cureus.74245.
Favorable efficacy of adalimumab treatment in experimental acute pancreatitis model.
Cakir Guney B, Tanoglu A, Yeniceri M, Cirak Z, Sade A, Tastan Y Turk J Med Sci. 2023; 52(6):1821-1828.
PMID: 36945982 PMC: 10390199. DOI: 10.55730/1300-0144.5528.
Etanercept - A culprit agent in acute pancreatitis?.
Gunawan F, Fayyaz B, Mihardja T J Community Hosp Intern Med Perspect. 2019; 9(2):147-149.
PMID: 31044047 PMC: 6484468. DOI: 10.1080/20009666.2019.1593783.
The protective effects of rutaecarpine on acute pancreatitis.
Yan L, Li Q, Rong Y, Chen Y, Huang Z, Wang Z Oncol Lett. 2018; 15(3):3121-3126.
PMID: 29435045 PMC: 5778859. DOI: 10.3892/ol.2017.7659.
Cakir O, Esen H, Toker A, Ataseven H, Demir A, Polat H Int J Clin Exp Med. 2016; 8(10):17551-64.
PMID: 26770346 PMC: 4694246.